Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
When do you recommend adjuvant trastuzumab for completely resected uterine cancer and for how long do you give it?
Related Questions
In general, how do you manage patients with early-stage endometrioid endometrial cancer who have concomitant POLE and TP53 mutations?
What are your top takeaways in Gyn Cancers from ASCO 2025?
Would you consider adding immunotherapy to adjuvant chemotherapy in a patient with incompletely staged, high-grade, MSI-H, POLE-mutated endometrioid carcinoma of the ovary with ultra-high tumor mutation burden on NGS?
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
For a patient with locally current endometrial cancer whose disease had complete radiographic response to carboplatin, Taxol, and pembrolizumab, would you consider adding radiation therapy?
For a borderline ovarian tumor that has been resected with BSO and hysterectomy, would you consider endocrine therapy if found to be ER-positive?
Have you had patients who wish to take ivermectin and/or fenbendazole as adjunct treatments for gynecologic cancers, and if so, how have you handled this?
What is your experience with in vitro chemosensitivity testing?
Have treatment recommendations changed for Stage I endometrial Cancer based upon PORTEC 4 results?
